Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Triclosan Antiseptic Category I Status Requested By CIBA

This article was originally published in The Tan Sheet

Executive Summary

FDA should consider new safety data supporting Category I (safe and effective) status for triclosan in the OTC Tentative Final Monograph for Health Care Antiseptic Drug Products, CIBA Specialty Chemicals and an alliance of six triclosan manufacturers/marketers state in a Sept. 13 citizen petition.

You may also be interested in...



Ciba Seeks FDA Clarification On Possible Triclosan “Data Gaps”

Ciba Specialty Chemicals is seeking a meeting with FDA staff to discuss "outstanding issues" relating to triclosan safety, the company says in a recent letter to the agency

Ciba Seeks FDA Clarification On Possible Triclosan “Data Gaps”

Ciba Specialty Chemicals is seeking a meeting with FDA staff to discuss "outstanding issues" relating to triclosan safety, the company says in a recent letter to the agency

Triclosan Antigingivitis/Antiplaque Monograph Status Sought By Ciba

Ciba Specialty Chemicals requests that FDA include triclosan in its upcoming OTC monograph for antigingivitis/antiplaque oral care products in a recently-filed application

Related Content

Topics

UsernamePublicRestriction

Register

PS093068

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel